GlassScriptPhysician profile
Lawrence J Lahatte
NPI 1902994023
$8,738.96
in general payments reported to CMS, 2019-2025
35 companies · $1,738 in 2025
The $1,738 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,183 · 2020: $1,007 · 2021: $1,153 · 2022: $1,440 · 2023: $1,082 · 2024: $1,136 · 2025: $1,738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,921 · Education: $35.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,920.69 |
| Education | $35.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,079.58 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,184.52 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $942.46 | 2019-2025 | Tremfya, Stelara, Simponi |
| Fujifilm Healthcare Americas Corporation | $631.11 | 2020-2021 | |
| Pfizer INC. | $449.55 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $406.76 | 2019-2022 | |
| Madrigal Pharmaceuticals | $353.47 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $322.38 | 2019-2025 | Sucraid, Sucraid |
| Boston Scientific Corporation | $279.79 | 2019-2022 | |
| Gilead Sciences, INC. | $224.70 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $190.42 | 2019-2025 | Entyvio |
| Celgene Corporation | $184.93 | 2022-2024 | Zeposia |
| Genzyme Corporation | $151.99 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $140.03 | 2020-2024 | Rebyota |
| Merck Sharp & Dohme LLC | $128.03 | 2021-2024 | Dificid |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $121.03 | 2022-2023 | |
| Covidien LP | $106.90 | 2019 | |
| Aimmune Therapeutics, INC. | $103.32 | 2024-2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $85.04 | 2022-2025 | Dupixent |
| Axonics, INC. | $82.51 | 2024 | Axonics |
| Lilly USA, LLC | $82.21 | 2024-2025 | Omvoh |
| Ucb, INC. | $66.89 | 2019 | |
| Ironwood Pharmaceuticals, INC | $65.21 | 2021-2024 | Linzess |
| Allergan, INC. | $59.07 | 2019 | |
| Intercept Pharmaceuticals, INC. | $54.86 | 2019-2025 | |
| Shionogi INC | $50.01 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $41.92 | 2024-2025 | Voquezna |
| Biocon Biologics INC | $23.92 | 2025 | Yesintek |
| Alexion Pharmaceuticals, INC. | $22.61 | 2019 | |
| Shield Therapeutics INC | $19.58 | 2025 | |
| Celltrion USA INC. | $19.44 | 2024 | Zymfentra |
| Ardelyx, INC. | $19.00 | 2024 | Ibsrela |
| Redhill Biopharma INC. | $15.36 | 2021 | |
| Amgen INC. | $15.21 | 2023 | Avsola, Amjevita |
| Organon LLC | $15.15 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Lahatte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.